| Identification | Back Directory | [Name]
9-CHLORO-2-(2-FURANYL)-5-[(PHENYLACETY)AMINO][1,2,4]-TRIAZOLO[1,5-C] QUINAZOLINE | [CAS]
183721-15-5 | [Synonyms]
MRS 1220
MRS 1220 solid
9-CHLORO-2-(2-FURANYL)-5-((PHENYLACETYL)AMINO)-[1,2,4]TRIAZOLO[1,5-C]QUINA
9-chloro-2-(2-furanyl)-5-((phenylacetyl)amino)-[1,2,4]triazolo[1,5-c]quinazoline
9-CHLORO-2-(2-FURANYL)-5-[(PHENYLACETY)AMINO][1,2,4]-TRIAZOLO[1,5-C] QUINAZOLINE
N-[9-CHLORO-2-(2-FURANYL)[1,2,4]-TRIAZOLO[1,5-C]QUINAZOLIN-5-YL]BENZENE ACETAMIDE
Benzeneacetamide, N-[9-chloro-2-(2-furanyl)[1,2,4]triazolo[1,5-c]quinazolin-5-yl]-
MRS 1220;9-CHLORO-2-(2-FURANYL)-5-[(PHENYLACETY)AMINO][1,2,4]-TRIAZOLO[1,5-C] QUINAZOLINE;N-[9-CHLORO-2-(2-FURANYL)[1,2,4]-TRIAZOLO[1,5-C]QUINAZOLIN-5-YL]BENZENE ACETAMIDE;MRS 1220;9-CHLORO-2-(2-FURANYL)-5-((PHENYLACETYL)AMINO)-[1,2,4]TRIAZOLO[1,5-C]QUINA
MRS 1220;9-CHLORO-2-(2-FURANYL)-5-[(PHENYLACETY)AMINO][1,2,4]-TRIAZOLO[1,5-C] QUINAZOLINE;N-[9-CHLORO-2-(2-FURANYL)[1,2,4]-TRIAZOLO[1,5-C]QUINAZOLIN-5-YL]BENZENE ACETAMIDE;MRS 1220;9-CHLORO-2-(2-FURANYL)-5-((PHENYLACETYL)AMINO)-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLINE | [Molecular Formula]
C21H14ClN5O2 | [MDL Number]
MFCD01321046 | [MOL File]
183721-15-5.mol | [Molecular Weight]
403.82 |
| Chemical Properties | Back Directory | [density ]
1.49±0.1 g/cm3(Predicted) | [storage temp. ]
Store at RT | [solubility ]
DMSO: 2 mg/mL | [form ]
solid | [pka]
8.17±0.46(Predicted) | [color ]
white |
| Hazard Information | Back Directory | [Uses]
MRS 1220 is a highly potent and selective human Adenosine A3-R antagonist. | [Definition]
ChEBI: N-[9-chloro-2-(2-furanyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl]-2-phenylacetamide is a member of quinazolines. | [Biological Activity]
A potent and highly selective antagonist at the human A 3 adenosine receptor (K i values are 0.65, 305, and 52 nM at hA 3 , rA 1 and rA 2A respectively. Displays an IC 50 value > 1 μ M for inhibition of binding to rat A 3 receptors). | [in vivo]
MRS1220 (0.15 mg/kg; intraperitoneal inoculation) reduces tumor size and blood vessel formation in vivo. MRS1220 exhibits a strong in vivo anti-angiogenic effect[2]. | Animal Model: | Eight, 8 week-old male Sprague-Dawley rats bearing C6 (GSCs)[2] | | Dosage: | 0.15 mg/kg/72 h | | Administration: | Administered by intraperitoneal inoculation, for fifteen days | | Result: | A reduction close to 80% and 90% in tumor volume compared to the vehicle-treated group at day ten and fifteen post-treatment, respectively.
|
| [storage]
Store at RT |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|